Days after China’s regulators cleared the country’s fifth PD-1 checkpoint inhibitor for marketing, both excitement and anxiety is emerging over the increasingly overcrowded oncology research area in the country.
China is already the largest market in Asia for oncology drugs, as it has the largest patient population for several forms of cancer including lung, breast and liver
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?